Analysts say these ASX 300 shares are buys with 14% to 25% upside

Great returns could be on the cards for buyers of these shares according to analysts.

| More on:
Two brokers analysing stocks.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Are you on the lookout for some new additions to your portfolio in December?

If you are, it could pay to look at the two ASX 300 shares that brokers have just put buy ratings on.

Here's what they are saying about them:

Monash IVF Group Ltd (ASX: MVF)

Morgans thinks that this ASX 300 share could be fertile ground to grow an investment.

The broker likes Monash IVF, which is one of the largest fertility clinic operators in the country, due to its attractive valuation and strong structural demand.

Commenting on its recent trading update, the broker said:

MVF has provided a trading update at its AGM for performance YTD (up to October) and has provided guidance for 1H25 of underlying NPAT between $15.5-16.0m and continues to expect both revenue and underlying NPAT growth in FY25. Australian ARS industry cycles were weak in July and August, particularly in VIC, QLD and SA, but have since rebounded to see industry stimulated cycle growth up 2.9%. MVF is tracking slightly below industry, although maintaining market share on the pcp. The South East Asian business continues to gather momentum with strong growth YTD following a strong 2H24.

Despite continued cost pressures, MVF has maintained EBITDA margins YTD largely through patient price increases. We have made minor downward revisions to our earnings but continue to see strong structural demand drivers for MVF, we maintain our Add recommendation with a $1.50 price target (was $1.54).

Based on its current share price of $1.20, this price target implies potential upside of 25% for investors over the next 12 months.

NIB Holdings Limited (ASX: NHF)

This morning, Goldman Sachs has retained its buy rating and $6.50 price target on this health insurance company's shares.

This follows the release of quarterly data which showed that participation rates have improved. Outside this, the broker believes NIB is a buy due to its defensive earnings and favourable trading conditions. It said:

NHF is a private health insurer with operations across Australian residents health insurance, New Zealand health insurance, International health insurance and Travel. We are Buy-rated on NHF given: 1) It offers defensive exposure to the private health insurance sector 2) The claims environment (utilisation / inflation) is generally manageable albeit until recently 3) NHF policyholder growth has been better than industry, 4) Expense buffers available to support margins and 5) Strong approved rate increases.

Based on its current share price of $5.70, Goldman's price target implies potential upside of 14% over the next 12 months. The broker also expects a 4.5% dividend yield in FY 2025.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A young man punches the air in delight as he reacts to great news on his mobile phone.
Broker Notes

These ASX 200 shares could rise 30% to 50%

Brokers have good things to say about these cheap shares.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Broker Notes

10 Aussie stocks to buy in FY 2026

Let's see which shares analysts think could be buys in the upcoming financial year.

Read more »

watch
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Mum playing with her baby boy holding him on her tummy as she lays down while smiling about the Bubs share price going up today
Broker Notes

Following two unfortunate incidents, what's Macquarie's price target on Monash IVF shares?

Is Monash IVF a buying opportunity?

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Macquarie tips 18% return for this ASX 200 stock

The broker thinks this blue chip's profits are going to rebound in FY 2026.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Broker Notes

Bell Potter names more of the best ASX 200 shares to buy in FY26

These shares are among the best to buy in the new financial year according to its analysts.

Read more »

Suncorp share price Businessman cheering and smiling on smartphone
Broker Notes

5 ASX 200 shares for smart investors to buy in July

Brokers think these shares could be in the buy zone ahead of the new month.

Read more »